Skip masthead and go to navigation, main content or sidebar.

Penn State shield. Click to visit main Penn State website CIDD, the Center for Infectious Disease Dynamics. Click to visit our home page

Search   …this site   …Penn State  

Published 2006

Shorter TB treatment could cut deaths

What did the poet Keats, the composer Chopin and the writer Emily Bronte have in common? They all died before 1850 — of tuberculosis (TB), a disease we are still struggling to control a century and a half later. Over the last 25 years, TB has developed resistance to many antibiotics. Worldwide, it now kills at least 2 million people annually. Effective treatments are complicated, requiring sufferers to take drug cocktails over long periods (6 months or more). However, some new candidate drugs are currently being tested; some of these would allow shorter treatment periods.

Black and white lung XRay

X-ray through
lungs of TB patient.
Image courtesy of
Public Health Image
Library
, no. 2543

People who default on treatment more are likely to:

So, in theory, cutting the duration of TB therapy could slow the disease's spread, by reducing the chance of patients failing to complete treatment.

This hypothesis is supported by a study published in PLoS Medicine by a group of researchers that included Jamie Lloyd-Smith from CIDD. Using mathematical models based on real epidemic data, they found that cutting treatment duration to two months might prevent roughly a fifth of new cases and a quarter of all deaths in South East Asia between 2012 and 2030. They also show that the impact could be even greater where treatment default is currently high, and where shorter treatments are accompanied by better case detection.

» Read the paper on the PLoS Medicine website

Details

Authors: Joshua A. Salomon, James O. Lloyd-Smith, Wayne M. Getz, Stephen Resch, María S. Sánchez, Travis C. Porco, Martien W. Borgdorff

Title: Prospects for advancing tuberculosis control efforts through novel therapies

Journal: PLoS Medicine 3, e273

doi: 10.1371/journal.pmed.0030273


TB is a major killer of people whose immune systems are weakened by HIV, so ongoing work is examining how shorter treatment courses might affect TB in regions with high HIV prevalence. For more information, contact Jamie Lloyd-Smith.